Novo Nordisk hopes to stabilize Wegovy supply in early 2022
Production of obesity drug Wegovy is still expected to experience delays for the rest of 2021, but should, however, be stabilized in early 2022, the pharmaceutical company reports.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk has significantly increased the production of its weight loss drug Wegovy, which is in high demand, and is now hoping to have stabilized its supply early next year, the company writes in an update on its website.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk hires Queen Latifah for US marketing offensive
For subscribers
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers
